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Albuminuria is an independent risk factor for the progression to
end-stage kidney failure, cardiovascular morbidity, and premature
death. As such, discovering signaling pathways that modulate
albuminuria is desirable. Here, we studied the transcriptomes of
podocytes, key cells in the prevention of albuminuria, under diabetic
conditions. We found that Neuropeptide Y (NPY) was significantly
down-regulated in insulin-resistant vs. insulin-sensitive mouse podo-
cytes and in human glomeruli of patients with early and late-stage
diabetic nephropathy, as well as other nondiabetic glomerular dis-
eases. This contrasts with the increased plasma and urinary levels of
NPY that are observed in such conditions. Studying NPY-knockout
mice, we found that NPY deficiency in vivo surprisingly reduced the
level of albuminuria and podocyte injury in models of both diabetic
and nondiabetic kidney disease. In vitro, podocyte NPY signaling oc-
curred via the NPY2 receptor (NPY2R), stimulating PI3K, MAPK, and
NFAT activation. Additional unbiased proteomic analysis revealed that
glomerular NPY-NPY2R signaling predicted nephrotoxicity, modu-
lated RNA processing, and inhibited cell migration. Furthermore,
pharmacologically inhibiting the NPY2R in vivo significantly re-
duced albuminuria in adriamycin-treated glomerulosclerotic mice.
Our findings suggest a pathogenic role of excessive NPY-NPY2R
signaling in the glomerulus and that inhibiting NPY-NPY2R signal-
ing in albuminuric kidney disease has therapeutic potential.
Chronic kidney disease (CKD) is a major global healthcareconcern, affecting over 10% of the general population, and
frequently occurs secondary to other systemic disorders including
diabetes, obesity, hypertension, and the metabolic syndrome. A
common early hallmark of CKD is albuminuria, which not only
reflects damage to the glomerular filtration barrier (GFB) in the
kidney but also is an important independent risk factor for the pro-
gression to end-stage renal failure and cardiovascular disease (1–3).
Thus, strategies to prevent albuminuria have important therapeutic
potential, particularly in the early stages of CKD progression.
Podocytes are highly specialized epithelial cells of the glomer-
ulus, lining the urinary side of the filtration barrier. Owing to their
complex, dynamic structures and their ability to secrete (and adapt
to) a number of growth factors, these cells have a central role in
filtration barrier maintenance (4). As such, podocyte damage is a
key driver of albuminuria and glomerular disease in numerous
settings and occurs early in the pathogenesis of many albuminuric
conditions (5–9).
While it is well-established that podocyte damage is a major
cause of albuminuria (8), the pathways and molecules involved in
podocyte injury are incompletely understood. We (10, 11) and others
(12, 13) have highlighted the importance of podocyte insulin
responses in maintaining glomerular function, and it is now evident
that circulating factors associated with common systemic disorders,
including diabetes, obesity, and the metabolic syndrome, can directly
induce podocyte insulin resistance (14–17) and associated damage
(15, 18). In this study, we analyzed the transcriptomes of insulin-
sensitive and insulin-resistant podocytes with the aim of identifying
molecules that are differentially regulated in podocyte damage,
which may play a role in albuminuric kidney disease. This unbiased
transcriptome analysis revealed that Neuropeptide Y (Npy) was the
most highly down-regulated transcript in insulin-resistant vs. insulin-
sensitive podocytes. Analysis of patient cohorts also revealed a sig-
nificant reduction in glomerular NPY expression in both early and
late-stage diabetic nephropathy (DN), as well as in several other
human albuminuric conditions. This contrasts with the increased
plasma and urinary levels of NPY that are observed in diabetes and
CKD (19–22). This prompted us to further investigate the potential
role of NPY (and NPY signaling) in the podocyte and glomerulus.
Results
Npy Expression Is Reduced in Diabetic, Insulin-Resistant Podocytes
and Glomeruli. To explore factors associated with podocyte in-
jury, we initially performed nonbiased RNA sequencing of highly
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insulin-sensitive mouse podocytes [with stable insulin receptor
expression (14)] and insulin-resistant mouse podocytes [with
insulin resistance induced via exposure to a combination of in-
flammatory cytokines, high insulin, and high glucose, as pre-
viously reported (14)]. Of over 23,000 transcripts, Npy was the
most highly down-regulated in the insulin-resistant cells (46.53-
fold reduction, P < 5.22 ! 10!181), in comparison with highly
insulin-sensitive podocytes (Fig. 1A and SI Appendix, Fig. S1). A
significant reduction in Npy was also observed in RNA sequencing
of control mouse podocytes (insulin-sensitive, without stable in-
sulin receptor expression), when compared to the insulin-resistant
cells (5.56-fold reduction, P < 3.06 ! 10!33, SI Appendix, Fig. S1).
A B
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Fig. 1. Npy mRNA is significantly down-regulated in
insulin-resistant podocytes and diabetic mouse glo-
meruli. (A) Genes down-regulated in insulin-resistant,
compared with insulin-sensitive, mouse podocytes
(podocytes exposed to 1 ng/mL TNF!, 1 ng/mL IL-6,
100 nmol/L insulin, and 25 mmol/L glucose or stably
expressing the insulin receptor, respectively) identified
by RNA sequencing. (B) Results of focused insulin sig-
naling qPCR arrays performed on podocytes treated
with 1 ng/mL TNF-! and IL-6, demonstrating a signif-
icant reduction in Npy expression following cytokine
treatment; n = 3. (C) RT-PCR and (D) qPCR results
confirming a reduction in Npy in insulin-resistant
podocytes in vitro (Ins Res, following exposure to 1 ng/mL
TNF!, 1 ng/mL IL-6, 100 nmol/L insulin, and 25 mmol/L
glucose) (n = 5). *P < 0.05. (E) Data from Nephroseq.
Npy expression (log2 median-centered intensity) in
the Hodgin Diabetes Mouse Glom dataset sorted by
fasting blood glucose: nondiabetic, defined as <300
mg/dL (n = 23) vs. diabetic, defined as >300 mg/dL
(n = 16); under-expression gene rank 2,840 (in top




Fig. 2. Glomerular NPY expression is significantly
down-regulated in human renal disease. (A) NPY
expression (log2 mRNA intensity) in Pima early di-
abetic nephropathy (DN, n = 69) vs. healthy living
donors (n = 18). *P < 0.05. (B) Data from Nephroseq:
NPY expression (log2 median-centered intensity) in
the Ju CKD Glom dataset: healthy living donor (n =
21) and DN (n = 12); under-expression gene rank
3,211 (in top 19%). *P < 0.05. (C) Correlation be-
tween glomerular NPY expression (log2 median-
centered intensity) and eGFR in the Ju CKD Glom
dataset: healthy living donors and diabetic ne-
phropathy, n = 33. (D) NPY expression (log2 median-
centered mRNA intensity) in Ju CKD Glom, showing
a significant regulation in glomerular NPY in FSGS
(n = 46), vasculitis (n = 44), lupus nephritis (n = 53),
arterial hypertension (n = 36), and thin basement
membrane disease (n = 24) vs. healthy living donors.
(E) qPCR results showing relative levels of NPY ex-
pression in human glomerular cell lines (Pod, podocytes;
Endo, glomerular endothelial cells; Mes, mesangial
cells); n = 3 to 5; *P < 0.05. (F) RT-PCR for NPY and
!-Actin in human glomerular cell lines under condi-
tions of active (33 °C) and inactive (37 °C) SV40 ex-
pression (Endo, glomerular endothelial cells; Pod1 and
Pod2, two independent human podocyte cell lines;
Mes, mesangial cells) and isolated human glomeruli.











































We also performed focused insulin-signaling qPCR arrays on
podocytes exposed to the inflammatory cytokines TNF-! and IL-
6, which become insulin-resistant with respect to glucose uptake
(SI Appendix, Fig. S2). Results from these arrays also revealed
that Npy was again the most significantly down-regulated tran-
script of 84 genes related to insulin signaling (Fig. 1B and SI
Appendix, Fig. S1). This reduction in Npy expression was further
confirmed in our insulin-resistant podocyte model using end-
point PCR (Fig. 1C) and qPCR (Fig. 1D). Analyzing data from
the large kidney transcriptomics database Nephroseq, we also
found a significant reduction in Npy expression in the glomeruli
of diabetic mice (Fig. 1E).
Modulation of Glomerular NPY Expression in Human Disease. To
evaluate whether NPY expression was reduced during the de-
velopment of human diabetic kidney disease, we studied glo-
merular NPY expression in both early and late-stage DN patient
cohorts (Pima diabetic patients and the Nephroseq “Ju CKD
Glom” dataset, respectively) (23, 24). A significant reduction in
NPY expression was observed in the glomeruli of patients with
both early (Fig. 2A) and advanced type 2 DN (Fig. 2B), when
compared with nondiabetic, healthy living donors. In the advanced
DN patient group, we found a significant correlation between the
level of glomerular NPY expression and estimated glomerular
filtration rate (eGFR) (Fig. 2C). Further analysis of the Ju CKD
Glom dataset revealed that glomerular NPY expression was sig-
nificantly reduced in several renal diseases, including focal seg-
mental glomerulosclerosis (FSGS), vasculitis, lupus nephritis,
hypertension, and thin membrane disease (Fig. 2D). Of the three
human glomerular cell types (podocytes, mesangial cells, and
glomerular endothelial cells), NPY was exclusively expressed in
podocytes (Fig. 2 E and F), although this expression was much
lower than that seen in neuronal-derived cell lines or the adrenal
gland (SI Appendix, Fig. S3).
NPY!/! Mice Have No Apparent Renal Phenotype under Basal Conditions.
To investigate the consequences of reduced glomerular NPY
expression on the development of albuminuria and podocyte
damage in vivo, we studied NPY knockout (NPY!/!) mice on a
nephropathy-prone 129Sv/Ev background. These mice maintain
normal body weight and glucose and insulin levels under basal
conditions (25). When we compared NPY!/! to age- and sex-
matched wild-type (WT) control animals, despite undetectable
Npy levels in NPY!/! mice (Fig. 3A), we observed no significant
differences in the degree of albuminuria (Fig. 3B) or renal his-
tology (Fig. 3C) under basal conditions. Importantly, as NPY has
important cardiovascular roles (26–30), we did not detect any
differences in baseline blood pressure parameters (systolic blood
pressure [SBP] and pulse rate in beats per minute) between the
WT and NPY!/! mice (Fig. 3 D and E).
Diabetic NPY-Deficient Mice Are Protected from Albuminuria and
Podocyte Damage. To explore the effect of NPY deficiency on
the development of diabetic nephropathy, we compared the ex-
tent of albuminuria and glomerular damage in streptozotocin
(STZ)-induced diabetic NPY!/! and WT mice. There were no
significant differences in nonfasting blood glucose levels between
WT and NPY!/! groups 8 wk after administration of STZ (Fig.
4A) as previously reported (31). However, in contrast to WT
diabetic animals, which demonstrated significantly elevated uri-
nary albumin:creatinine ratios (uACRs), diabetic NPY!/! mice
had no significant increase in uACRs when compared with citrate-
treated control animals 24 wk after the induction of diabetes (Fig.
4B). A fourfold increase in albuminuria was observed in WT mice
(P = 0.036 WT citrate vs. STZ). No significant increase in albu-
minuria was observed in NPY!/! mice (P = 0.6828 NPY!/! citrate
vs. STZ). Serum creatinine and urea levels remained normal in all
experimental groups (SI Appendix, Fig. S4). Kidney tissue displayed
evidence of mild mesangial matrix deposition and a small number of
protein casts in the tubular regions of bothWT and NPY!/! diabetic
animals (Fig. 4C) with no significant differences in histological
scores between groups (SI Appendix, Fig. S4 D and E), reflecting
the mild renal phenotype of this STZ diabetic model. When an-
alyzing the GFB ultrastructure, however, we observed that podo-
cyte foot process (FP) architecture was significantly protected in
diabetic NPY!/! animals when compared to diabetic WT controls




Fig. 3. Glomerular structure and function is normal in NPY!/! mice under
basal conditions. (A) No detection of Npy transcript in kidneys from NPY!/!
mice, compared with WT control kidney tissue, using qPCR; n = 3 per group.
***P < 0.001. (B) uACRs in WT (n = 11) and NPY!/! mice (n = 13). (C) Periodic
acid–Schiff (PAS) staining of kidney tissue from WT and NPY!/! mice at 4 mo
of age confirmed no significant histological abnormalities in these animals
(n = 4 per group). (D) SBP measurements and (E) pulse rate (beats per
minute, BPM) in WT (n = 3) and NPY!/! (n = 4) mice, 5 to 10 inflation cycles
per mouse.

































NPY-Deficient Mice Are Protected from Albuminuria and Podocyte
Damage in Adriamycin Nephropathy. To investigate whether NPY
deficiency was also protective in other, nondiabetic models of
proteinuric kidney disease, we further studied the extent of
kidney damage in adriamycin nephropathy (AN), a model typi-
cally characterized by podocyte injury, followed by glomerulo-
sclerosis, inflammation, and fibrosis (32, 33). AN was induced in
male WT or NPY!/! mice by a single intravenous (i.v.) injection
of adriamycin (ADR) at concentrations of 6 mg/kg. There was no
evidence of kidney disease in WT or NPY!/! vehicle-injected
control animals (SI Appendix, Fig. S5). However, 14 d following
adriamycin administration, NPY!/! mice had significantly lower
uACRs than WT animals (Fig. 5A). Although a mild histological
phenotype was observed in both WT and NPY!/! groups, there
was evidence of tubular dilation and protein casts inWT-ANmice,
which was absent in the NPY!/! AN group, reflecting the reduction
in albuminuria in the NPY!/! animals (Fig. 5B and SI Appendix,
Fig. S6). No significant differences in the levels of serum creat-
inine or urea were observed between experimental groups (SI
Appendix, Fig. S6). Consistent with the reduction in albuminuria,
ultrastructural analysis again demonstrated a significant reduction
in FP effacement in NPY!/! animals, compared with WT-AN
mice (Fig. 5 C–E).
Exogenous NPY Signals to Podocytes via NPY2R. Given that a sys-
temic knockout of NPY protected against albuminuria and
podocyte ultrastructural damage in two in vivo models, we next
investigated the possibility that circulating NPY could influence
podocyte responses at the filtration barrier. Indeed, increases in
plasma NPY are reported in several systemic conditions linked
to albuminuria including obesity, diabetes, and hypertension




Fig. 4. STZ-treated NPY!/! mice are protected from
albuminuria and podocyte damage. Diabetes was in-
duced in male NPY knockout (NPY!/!) 129/Sv and WT
129/Sv mice aged 6 to 8 wk with i.p. injections of 50
mg/kg STZ dissolved in sodium citrate buffer (pH 4.5)
for 5 consecutive days. Tissue was collected 24 wk after
administration of STZ. (A) Nonfasted blood glucose
was significantly higher in both WT and NPY!/! ani-
mals from 8 wk after STZ injection; ***P < 0.001, with
no differences between the two diabetic groups. (B) A
significant increase in the uACR in STZ-treated WT
mice 24 wk after injection. *P = 0.036 WT STZ (n = 10)
vs. WT Citrate (n = 4), no significant increase in STZ-
treated NPY!/! animals (n = 8) when compared with
NPY!/! citrate-treated mice (n = 5). (C) PAS staining
presented evidence of sclerosis in some glomeruli of
each diabetic cohort, and small protein casts could be
seen in tubules of each model (black arrow). (Scale bar,
25 "m.) (D) Electron microscopy (EM) images of STZ-
treated WT and NPY!/! mice. (Scale bar, 500 nm.) (E)
Quantification of podocyte FP width as a measure-
ment of effacement; n = 3 mice per experimental
group, >20 regions per mouse; **P < 0.01.











































expressed by renal cells (39–42), including our glomerular cell
models (SI Appendix, Fig. S7). Initial dose–response and time-
response experiments demonstrated that the stimulation of
both human and mouse podocytes with NPY induced the ac-
tivation of PI3K and ERK MAPK phosphorylation cascades, as
shown by increased phosphorylation of Akt (S473, T308) and
p44/42 MAPK (Thr202/Tyr204), respectively (SI Appendix, Fig.
S8). Using specific chemical NPY receptor antagonists, we also
found that blocking NPY1R with BIBP3226 had no significant
effect on these signaling responses (Fig. 6A), whereas the
pretreatment of podocytes with the specific NPY2R antagonist
BIIE0246 (43) blocked the NPY-stimulated phosphorylation of
Akt and p44/42 MAPK (Fig. 6B).
NPY Promotes NFAT-Nuclear Translocation in Podocytes via a
Calcium-Dependent Pathway. Furthermore, we found that NPY
stimulation caused an increase in intracellular calcium concen-
trations (SI Appendix, Fig. S9) and induced the nuclear trans-
location of NFAT-eGFP (in a calcineurin-dependent manner)
(Fig. 7 A–D). When analyzing whole-cell populations, a signifi-
cant increase in the nuclear-localized NFAT-eGFP was evident
30 and 60 min post stimulation, which was blocked when podocytes
were pretreated with cyclosporine (CsA) (Fig. 7 B and C). This was
also associated with an increase in expression of the NFAT-regulated
gene, regulator of calcineurin 1 (Rcan1) (44) (Fig. 7E), which was
blocked in the presence of BIIE0246, demonstrating that NPY sig-
naling can promote calcium-dependent NFAT activity in podocytes.
Inhibiting NPY2R In Vivo Reduces Albuminuria in Adriamycin Nephropathy.
To determine whether NPY-NPY2R signaling influenced albuminuria
in vivo, we investigated the effects of BIIE0246 on the development
of AN. Male BALB/c mice were treated with BIIE0246 at 10
"g/day via daily intraperitoneal (i.p.) injection or subcutaneous
osmotic minipump and albuminuric kidney damage was induced
with a single i.v. injection of ADR. Of note, we observed a re-
duction in Npy messenger RNA (mRNA) in podocytes treated
with ADR (SI Appendix, Fig. S10A) and an increase in plasma
Npy levels in AN mice, which was not affected by BIIE0246
treatment (Fig. 8A). Fourteen days after the induction of AN,
mice treated with the NPY2R antagonist had significantly reduced
uACRs, when compared to vehicle control-treated animals (Fig.
8B), with no significant changes in body weight between any of the
experimental groups (SI Appendix, Fig. S10C). Importantly, al-
though a significant increase in SBP was observed in adriamycin-
treated animals, there was no significant change in SBP between
AN-vehicle and AN-BIIE0246 groups (Fig. 8C), indicating that the
protective effects of BIIE0246 treatment on albuminuria were in-
dependent of any blood pressure-lowering effects. Furthermore, we
observed an improvement in renal histology (Fig. 8D and SI Ap-
pendix, Fig. S10 D and E) and a maintenance of podocyte FP
architecture (Fig. 8 E–G) in AN-BIIE0246 mice, compared with
the AN-vehicle group. Collectively, these results suggest that
pharmacologically targeting NPY-NPY2R signaling is beneficial in
albuminuric kidney disease.
Proteomic Analysis of Glomerular NPY-NPY2R Signaling Networks. To
further explore the effects of NPY in the glomerulus (and po-
tential protective effects of NPY2R antagonism), we performed
high-resolution Tandem Mass Tagged (TMT)-based spectrometry




Fig. 5. NPY!/!mice are protected from albuminuria and
podocyte damage in low-dose adriamycin nephropathy.
Adriamycin was administered to male NPY knockout
(NPY!/!) 129/Sv andWT 129/Svmice at 6mg/kg via a single
i.v. injection under mild anesthesia. Tissue was collected
14 d following adriamycin injection. (A) uACRs were
significantly lower in the NPY!/! AN group compared
with WT ANmice (*P < 0.05, n = 7 WT 3 d, n = 5 NPY!/!
3 d, n = 10 WT 14 d, n = 10 NPY!/! 14 d); (B) PAS
staining demonstrated evidence of sclerosis in some
glomeruli of each AN group with mild tubular dilation
and protein casts in WT AN mice (black arrow). (C) EM
images of WT and NPY!/! AN mice. (D) Quantification
of podocyte FP width. (E) The number of FPs per glo-
merular basement membrane (GBM) length as a mea-
surement of effacement, demonstrating a significant
reduction in FP effacement in NPY!/! AN compared with
WT AN mice (***P < 0.001 n = 3/group, >20 regions per
mouse).

































chronic (24-h) or acute (10-min) NPY stimulation, with or without
BIIE0246 incubation. Analysis of the total glomerular proteome
identified significant changes in 367 proteins after chronic (24-h)
NPY treatment (Fig. 9A). The activity of potential upstream regu-
lators of these proteins was predicted using Ingenuity Pathway
analysis (IPA) (45) (Fig. 9B), which suggested a significant increase
in activity of protein groups, including PI3K and MAPK (as in-
dicated by our in vitro studies) (Fig. 6). A full list of upstream
regulators, and proteins used to make these predictions, is pre-
sented in SI Appendix, Table S1.
Enrichment analysis was also performed in IPA and predicted
several “Canonical Pathways” (Fig. 9C and SI Appendix, Table
S2), and “Diseases and Biofunctions” (Fig. 9D and SI Appendix,
Table S3) were significantly altered with 24 h of NPY treatment.
These pathways were not predicted to be significantly enriched in
glomeruli treated with NPY in combination with BIIE0246. Of note,
“Nephrotoxicity” and “Chronic Kidney Disease” were predicted,
significantly enriched bioprocesses in response to chronic NPY
stimulation (Fig. 9D and SI Appendix, Table S3). BIIE0246
caused a significant disruption in these responses. Of the glomerular
proteins that were regulated by NPY, changes in Rps2, Tcaf1,
Aldh18a1, Vkorc1l1, Nudt12, Lsm5, Sec16a, Aqr, Tor3a, Ttc7a, and
Nup107 were most significantly inhibited by NPY2R antagonism
(Fig. 9 E and F). Several of these proteins are involved in RNA
processing. In NPY+BIIE0246-treated glomeruli, we found 69
significantly regulated proteins (Fig. 9G). IPA analysis predicted a
significant inhibition of TP53 under these conditions, and a signif-
icant enrichment in notch signaling and innate immune responses
(Fig. 9 H–J and SI Appendix, Table S4), suggesting that these NPY-
stimulated responses do not occur via the NPY2R.
Phospho-proteomic analysis.We also studied the glomerular phospho-
proteome after acute (10-min) and chronic (24-h) NPY stimulation,
which identified significant changes in phosphorylation of 169
and 159 glomerular proteins, respectively, when normalized to
corresponding total protein levels (Fig. 10 A and B). The top 10
phospho-proteins regulated by NPY that were blocked by NPY2R
antagonism are presented in Fig. 10 C and D. IPA analysis of the
glomerular phosphoprotein changes predicted a significant en-
richment of several Canonical Pathways after 10 min of NPY
stimulation, which were no longer enriched with BIIE0246 treat-
ment (Fig. 10E and SI Appendix, Table S5), including a significant
activation of ERK/MAPK signaling, as demonstrated in mouse
podocytes in vitro (Fig. 6B). Downstream Disease and Biofunction
analysis suggested that the most significantly enriched and activated
processes in glomeruli treated acutely with NPY were those in-
volved in RNA post-transcriptional modifications, including in-
creased processing and splicing of RNA and mRNA, which were
inhibited by BIIE0246 treatment (Fig. 10F and SI Appendix, Table
S7). Phospho-proteins that we found to be regulated by NPY
stimulation involved in RNA processing are presented in Fig. 10G.
NPY induced changes in the phosphorylation of 21 proteins that
were sustained between 10 min and 24 h of NPY treatment (SI
Appendix, Fig. S11). Interestingly, when looking at biofunctions
regulated by both acute and chronic NPY treatment, IPA predicted
a significant inhibition of cellular migratory responses (including
cytoskeletal organization, number of cell protrusions, and cell
spreading) (Fig. 10H and SI Appendix, Table S8), which was again
reversed in glomeruli treated with BIIE0246 and NPY in combi-
nation (Fig. 10 I and J and SI Appendix, Table S9). This effect of
NPY on cell migration was further validated in vitro using podo-
cyte motility assays, which demonstrated a significant reduction in
podocyte movement in response to NPY (Fig. 10K).
Discussion
NPY is one of the most abundant peptides of the central and
peripheral nervous systems, with a significant role in energy
homeostasis (38, 46). Although its expression and release into
plasma is largely associated with sympathetic nervous system
(SNS) activity (47), several cells are now known to respond to
NPY, and dysregulation of the NPY system is implicated in
several pathological conditions including obesity (38), cardio-
vascular disease (29, 48), diabetes (49), and insulin resistance (50),
conditions which are also often accompanied by albuminuria and
CKD (1).
Interestingly, although the pathogenic involvement of NPY in
albuminuric kidney disease has not previously been explored,
increases in circulating NPY are observed in both the plasma and
urine of type 1 (21) and type 2 diabetic patients with nephrop-
athy (20), and the common Leu7pro7 polymorphism in the NPY
gene, thought to be associated with increased peptide secretion
(51), has been associated with proteinuria (52) and an increased
susceptibility to nephropathy in type 1 diabetic patients (53).
Recently, it has also been shown that increased plasma NPY levels
are associated with proteinuria, faster progression of CKD, and a
higher risk of kidney failure in two independent European cohorts
of CKD (19).
We initially hypothesized that reducing NPY levels would
contribute to glomerular disease and podocyte damage. However,
under basal conditions, NPY-deficient mice (25) had no apparent
kidney phenotype and no difference in levels of albuminuria. In
contrast, NPY-deficient mice were protected from albuminuria and
podocyte damage in both STZ-induced diabetes and adriamycin-
induced glomerular injury. These observations, coupled with the
knowledge that circulating NPY is often increased in conditions
A
B
Fig. 6. Podocytes respond to NPY in an NPY2R-
dependent manner. (A) Representative Western
blots and densitometry of differentiated mouse
podocytes treated with the Y1 receptor antagonist
BIBP3226 at 1 "M for 24 h prior to stimulation with
10 and 100 ng/mL NPY for 15 min, n = 4. **P < 0.01
and ***P < 0.001 vs. unstimulated, one-way ANOVA,
Tukey’s multiple comparison. (B) RepresentativeWestern
blots and densitometry of differentiated mouse podo-
cytes treated with the Y2 receptor antagonist BIIE0246
(1 "M) for 24 h prior to stimulation with 10 and 100 ng/
mL NPY for 15 min, n = 4. ***P < 0.001 vs. unstimu-
lated, one-way ANOVA, Tukey’s multiple comparison.














































Fig. 7. NPY stimulates calcium-dependent NFAT activation in podocytes. Podocytes were transfected with NFAT-eGFP and stimulated with 100 ng/mL of NPY
at indicated time points before fixation and DAPI staining. Where indicated, 10 "M CsA was added 15 min prior to NPY stimulation. Modest changes in
brightness and contrast were applied to all images for visual purposes; unmodified images were used for quantification. (A) Representative fluorescent
images. (B and C) Population average values for NFAT-eGFP nuclear:cytoplasmic (N:C) ratios derived from arbitrary fluorescence unit measurements of NFAT-
eGFP intensity in nuclear and cytoplasmic compartments and normalized to control (time 0), demonstrating a significant increase in N:C NFAT-eGFP at (B) 30
min and (C) 60 min post stimulation. *P < 0.05 and **P < 0.01, Mann–Whitney U test; no significant differences were observed with CsA pretreatment; n = 3;
each condition was tested in triplicate. (D) Percentage of activated cells (where N:C of individual cells >0.7) in whole-cell populations over time; n = 3. (E) qPCR
results demonstrating fold change in regulator of calcineurin 1 (Rcan1) expression following NPY stimulation, with and without costimulation of the Y2
receptor antagonist, BIIE0246, at 1 "M for 24 h; *P = 0.05, Mann–Whitney U test; n = 3.

































such as diabetes, obesity, hypertension, and CKD (19, 35–38),
suggested that increased circulating NPY might in fact contribute
to albuminuria, potentially by directly affecting the filtration bar-
rier. As such, our initial observations of reduced NPY mRNA in
diabetic podocytes and glomeruli may reflect a response to disease
to limit local glomerular NPY levels. This was supported by the
finding that podocyte NPY production was much lower than that of
neuronal cells (SI Appendix, Fig. S3), which are the major source of
circulating NPY.
NPY has been shown to have a direct effect on peripheral cells
in several conditions. For example, increased circulating NPY in
obesity can directly signal to adipocytes, via NPY2R, promoting adi-
pogenesis, thereby augmenting symptoms of the metabolic syndrome
and the obese phenotype (38); in diabetic retinopathy, NPY-NPY2R
signaling may contribute toward retinal neovascularization (54),
and NPY-NPY1R signaling to macrophages has antiinflammatory
effects in diet-induced obesity, with NPY1R deficiency exacerbating
obesity, insulin resistance, and inflammation (50). As such, the
pharmacological modulation of NPY receptor signaling is a prom-
ising strategy for several diseases, and NPY receptor ligands are
being trialled for the treatment of obesity (29). The potential for
NPY receptor ligands in the treatment of renal disease, however,
has not been investigated.
Our subsequent experiments using both human and mouse
podocytes revealed that NPY could directly signal to these cells via
NPY2R. Furthermore, the stimulation of podocytes with NPY
promoted NFAT activation via a calcineurin- (thus calcium-) de-
pendent pathway. Given that the overactivation of both NFATc1
(44, 55, 56) and NFATc3 (57, 58) is linked to podocyte damage,
it is feasible that increased NPY-NPY2R signaling to podocytes
directly contributes to albuminuria, in part via the activation of
Ca2+-calcineurin-NFAT pathways.
To investigate the therapeutic potential of modulating NPY2R
signaling in albuminuria, we further studied the effects of BIIE0246
treatment (43, 59) on the development of albuminuria in vivo.
We found a significant reduction in the level of albuminuria in
mice treated with the NPY2R antagonist when compared with
vehicle-treated mice in AN. This was coupled with an improve-
ment in renal histology and podocyte FP architecture. Impor-




Fig. 8. BIIE0246 treatment reduces albuminuria in ADR nephropathy. Adriamycin was administered to male BALB/c mice at 6 mg/kg via a single i.v. injection
under mild anesthesia, and the effects of NPY2R inhibition were investigated. Control mice were treated with equivalent volumes of distilled water
(adriamycin vehicle) and dimethylsulfoxide (BIIE0246 vehicle). (A) Plasma NPY levels (ng/mL) in male BALB/c mice treated with adriamycin (n = 8) or adriamycin
in combination with the NPY2R antagonist BIIE0246 (n = 4). (B) uACRs in mice treated with adriamycin (n = 15), adriamycin plus the NPY2R antagonist
BIIE0246 (n = 14), or vehicle (n = 3). A significant reduction in albuminuria is observed in the ADR+BIIE0246 group, compared with ADR+Vehicle group at 14 d.
(C) A significant increase in SBP was observed in ADR-treated mice (**P = 0.0087) which was not influenced by NPY2R inhibition (P = 0.3260). (D) PAS staining
demonstrating a reduction in the severity and extent of glomerular sclerosis and tubular dilation/protein accumulation in the ADR+BIIE0246 mice, al-
though evidence of tubular dilation and protein casts can be seen in both ADR-treated groups (black arrows). (E ) EM images of ADR+Vehicle- and
ADR+BIIE0246-treated mice, demonstrating a significant loss of podocyte architecture. (F ) Quantification of FP width. ***P < 0.001. (G) Number of FPs per
GBM length, indicating a significant reduction in FP effacement in ADR+BIIE0246-treated mice compared to ADR+Vehicle treatment; n = 3 mice >20
regions per mouse. **P < 0.01.

















































Fig. 9. Total proteomic analysis of mouse glomeruli treated with NPY ex vivo. Glomeruli were isolated and treated with NPY (100 ng/mL for 24 h) with or
without NPY2R inhibition (1 "M BIIE0246 for 24 h). (A) Changes in the total glomerular proteome following 24 h of NPY stimulation compared with basal
(control) glomeruli; Log2 fold change (FC) vs. !log10 P value of the scaled abundances. (B) Prediction of the upstream regulators of glomerular protein
changes after 24 h of NPY treatment determined by IPA; positive z-score: predicted activation; negative z-score: predicted inhibition. (C) Canonical pathway
and (D) Diseases and Biofunctions significantly enriched in mouse glomeruli treated with NPY for 24 h, which were not enriched in NPY+BIIE0246-treated
glomeruli, determined by IPA. Black bars: predicted activation; white bars: predicted inhibition; gray bars: no activity information predicted. (E) Heat map and
hierarchical clustering of z-scored scaled abundances normalized to basal values, demonstrating significant protein changes (24 h NPY) that are inhibited by
BIIE0246 treatment. (F) Log2 FC of scaled protein abundances at 24 h NPY relative to NPY+BIIE0246 treatment. (G) Changes in the total glomerular proteome
following 24 h of NPY + BIIE0246 treatment compared with basal; Log2 FC vs. !log10 P value of the scaled abundances. Nine proteins found to be significantly
regulated by BIIE0246 treatment alone were excluded from the analysis. (H) TP53 was highlighted as a significantly inhibited upstream regulator of protein
changes observed in NPY+BIIE0246-treated glomeruli. (I) “Notch signalling” was a significantly enriched canonical pathway. (J) Significantly enriched diseases
and biofunctions where three or more molecules were used to make the prediction.






































Fig. 10. Phospho-proteomic analysis of NPY-NPY2R signaling in mouse glomeruli. Glomeruli were isolated and treated with NPY (100 ng/mL for 10 min or 24
h) with or without NPY2R inhibition (1 "M BIIE0246 for 24 h). (A) Changes in the glomerular phospho-proteome following 10 min of stimulation (10! NPY)
compared with basal (control) glomeruli, Log2 FC vs. !log10 P value of the normalized phospho-peptide abundances. (B) Changes in the glomerular phospho-
proteome following 24 h of NPY stimulation (24 h NPY) compared with basal (control) glomeruli, Log2 FC vs. !log10 P value of the normalized phospho-
peptide abundances. (C) Heat map and unsupervised clustering of z-scored normalized phospho-peptide abundances, relative to basal conditions within each
experiment, showing the top 10 glomerular proteins significantly phosphorylated at 10 min and (D) 24 h of NPY treatment that was also inhibited by NPY2R
inhibition. (E) Significantly enriched Canonical Pathways based on significantly changed phospho-peptides at 10! NPY compared with basal, which were not
enriched in NPY+BIIE0246-treated glomeruli. Black bars: predicted activation; white bars: predicted inhibition; gray bars: no activity information predicted. (F)
Disease and Biofunction analysis in IPA predicted a significant enrichment and activation of RNA processing in glomeruli at 10! NPY (black bars: positive
activation z-score) and a significant inhibition in 10! NPY+BIIE0246-treated glomeruli when compared with 10! NPY treatment alone (white bars: negative
activation z-score). (G) Top 25 proteins with phospho-sites regulated by 10! NPY that are involved in RNA processing; bar chart demonstrates the normalized
phospho-peptide abundance ratios, relative to basal levels. (H) Disease and biofunction predicted to be enriched in glomeruli at both 10 min and 24 h NPY,
showing a sustained inhibition of cell migratory responses (white bars, negative z-score). Diseases and biofunctions were filtered to exclude those where
fewer than four phospho-peptides were used to make the predictions and where predicted activation/inhibition was inconsistent between 10 min and 24 h.
Data presented are for 24-h NPY-treated glomeruli. (I) Top 15 proteins with phospho-sites regulated by 24-h NPY stimulation, which are sensitive to BIIE0246
treatment and are involved in cell motility; bar chart demonstrates the normalized phospho-peptide abundance ratios relative to basal levels. (J) Disease and
biofunction predictions showing a significant enrichment and inhibition of cell migratory responses in glomeruli following NPY treatment when compared
with basal (white bars: negative z-score) and a significant enrichment and activation in NPY+BIIE0246-treated glomeruli when compared with NPY treatment
alone (black bars: positive z-score). (K) Representative images taken at baseline and 24 h following NPY stimulation and quantification of the migratory
response. The area of the clear zone was measured in pixels for each condition and compared to the area at time 0; *P < 0.05, one-way ANOVA, Tukey’s
multiple comparison; n = 3, 4 replicates per condition.











































and AN-vehicle groups, indicating that the protective effects on
albuminuria were independent of any effects on blood pressure.
This supports evidence suggesting that NPY-NPY1R signaling is
important in controlling blood pressure [and renal vasoconstric-
tion in hypertensive rat models (41)], as opposed to NPY-NPY2R
responses (26, 34, 60, 61).
We further found that, in ex vivo glomeruli, both acute and
chronic stimulation with NPY could regulate several signaling path-
ways, increasing posttranscriptional RNA processing and reducing
cell migration in an NPY2R-dependent manner. Taken together,
our results suggest that NPY-NPY2R signaling plays a direct,
pathogenic role in the glomerulus in albuminuric kidney disease.
As described, NPY is also a major component of the SNS; it
is present in renal nerve fibers where it is costored with norepi-
nephrine. Interestingly, several studies also describe direct, pro-
tective effects of denervation of the kidney [which is characterized by
reduced circulating NPY (62)], independent of changes in blood
pressure (63, 64). In the context of glomerular disease, renal de-
nervation protects against podocyte injury and albuminuria (64), and
drugs to reduce sympathetic nerve activity have been successfully
used to treat microalbuminuria in diabetic patients, despite having
no effect on blood pressure (65). Although we cannot determine the
role of SNS activity in our models per se, our results demonstrate
that NPY can have direct effects in the glomerulus and suggest a
pathogenic role for NPY2R signaling in albuminuria, in this regard,
supporting a direct role for overactivity of the SNS in kidney
damage. Furthermore, our results provide a potential mechanism
behind the association that others have observed between NPY and
albuminuria in DN and CKD (19, 20, 52, 53). The observation that
blocking NPY2R is protective also implicates other NPY family
members in albuminuria, in particular Peptide YY (39, 41).
In summary, using an unbiased RNA screening approach, we
identified NPY to be down-regulated in insulin-resistant podo-
cytes and diabetic glomeruli. However, our subsequent experi-
ments suggested that this NPY down-regulation was an adaptive
response (opposed to causative) and demonstrated that reducing
NPY-NPY2R signaling (opposed to NPYmRNA expression) was
protective in models of albuminuria. We found that NPY influ-
enced several signaling responses which were dependent on
NPY2R activity in the glomerulus. In podocytes, NPY activated
calcium-NFAT signaling and inhibited cell motility, both of
which may be detrimental if not properly regulated. Remarkably,
the chemical inhibition of NPY-NPY2R signaling in vivo pro-
tected against albuminuria and podocyte damage. Collectively,
these results demonstrate a direct effect of NPY at the filtration
barrier and suggest that targeting NPY-NPY2R signaling has
therapeutic potential in albuminuric kidney disease.
Materials and Methods
Please refer to SI Appendix for full detailed materials and methods.
Human Samples. Protocol human kidney biopsies were obtained from Pima
Indians (n = 69) with type-2 diabetes from the Gila River Indian Community
(23). Renal biopsies from healthy living donors (n = 18) were from the Eu-
ropean Renal cDNA Bank cohort (66). The study was approved by the In-
stitutional Review Board of the National Institute of Diabetes and Digestive
and Kidney Diseases, and each participant signed an informed consent
document. Kidney tissue processing, microarray preparation, and gene
expression profiling were done as described previously (66–68). Gene ex-
pression data were also extracted from the Nephroseq database (https://
www.nephroseq.org).
Animal Studies.All animal experiments and procedures were approved by the
UK Home Office in accordance with the Animals (Scientific Procedures) Act of
1986. Male NPY knockout (NPY!/!) mice were bred on a 129Sv/Ev back-
ground as previously reported (25). Diabetes was induced in mice aged 6 to
8 wk of age, with low-dose i.p. injections of 50 mg/kg STZ for 5 consecutive
days, resulting in a mild renal phenotype by 24 wk. ADR nephropathy was
induced with a single tail-vein injection of ADR at 6 mg/kg body weight. For
NPY2Ri studies, male BALB/c were treated with BIIE0246, a selective NPY2R an-
tagonist with minimal affinity for the Y1R and Y5R (43), at 10 "g/day for 14 d.
Cell Culture and Treatments. Conditionally immortalized human (69) and
mouse (70) podocytes were maintained as previously reported (14). Recombinant
full-length NPY was used at previously published concentrations (38), following a
2- to 6-h serum starvation. Selective antagonists of NPY1R (BIBP3226, Tocris) and
NPY2R (BIIE0246, Tocris) were used at 1 "M for 24 h. Where stated, 10 "M CsA
was added 15 min before stimulation with NPY. Adenovirus-expressing NFATC1-
eGFP (Ad-NFAT-GFP) was prepared and used as previously described (71).
Proteomic Analysis of Ex Vivo Glomeruli. Glomeruli were isolated by dynabead
perfusion frommale BALB/cmice as previously described (14, 72) and incubated
for 24 h in RPMI-1640 containing L-glutamine and NaHCO3, supplemented
with 10% fetal bovine serum (Sigma Aldrich) before appropriate stimulation.
Glomerular proteins were extracted in RIPA lysis and extraction buffer (Thermo-
Fisher) and prepared for TMT-based mass spectrometer analysis. All spectra
were acquired using an Orbitrap Fusion Lumos mass spectrometer controlled
by Xcalibur 4.1 software (Thermo Scientific). The data output from Proteome
Discoverer 2.1 was handled, processed, and further analyzed in Microsoft
Office Excel, GraphPad Prism, Perseus, and R. Log2-transformed scaled total
protein abundance data and adjusted phospho-peptide data were used for
analysis. Enrichment analysis was performed with IPA (45), using all detected
proteins/phosphoproteins in our TMT-MS/MS analysis as background.
Other Statistical Analysis. Unless otherwise stated, data are presented as
mean ± SEM and analysis were performed using GraphPad Prism (GraphPad
Software). Statistical significance was calculated with one-way ANOVA or
t tests and taken as P < 0.05. Normality tests and nonparametric tests were
performed accordingly.
Data Availability. All data related to this study are included either in the
paper, SI Appendix, or from the corresponding author upon reasonable
request. Detailed methods are provided in SI Appendix. The phospho-/total
proteomics data will be deposited in the PRoteomics IDEntification re-
pository as part of the ProteomeXchange Consortium.
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